 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral,Sublingual,rectal |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 17 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H12BrN5 |
| Molar mass | 354.211 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyrazolam (SH-I-04)[2] is abenzodiazepine derivative originally developed by a team led byLeo Sternbach atHoffman-La Roche in the 1970s.[3] It has since been "rediscovered" and sold as adesigner drug since 2012.[4][5][6]
Pyrazolam has structural similarities toalprazolam[7] andbromazolam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[4]
In the UK, pyrazolam has been classified as a Class C drug by section 5 of the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[8]
Unscheduled at the federal level.
Alabama made Pyrazolam a schedule I substance on March 18th, 2014.[9]
The condensation ofbromazepam (1) withmethylamine andtitanium tetrachloride gives theamidine (2). Treatment with nitrous acid gives the nitrosylation product (3). Further reaction withhydrazine gives (4), which is treated withtriethyl orthoacetate to complete the synthesis of pyrazolam.[10]
